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Abstract 
 
Colon cancer is a malignancy in gastrointestinal tract. It causes high mortality rate in 
global cancer population. However, chemotherapy as its first option therapy is still 
controversial due to its effectiveness and its adverse effects. Finding supportive and 
alternative drugs to cure cancer is one of focus in cancer research. A drug which also has 
anticancer effects is metformin. Metformin is a biguanide antidiabetic which show its potential 
anticancer benefit in metabolic-related cancers including colon cancer. To investigate 
anticancer potency of metformin in targeting p53-related molecules. Metformin treatment 
were divided into 4 groups by 0, 5, 10 and 20 mM concentrations and incubated in 37
°
C and 
5% CO2 condition for 48 hours. Immunohistochemistry were conducted to asses level of 
expression of Bax, p21, cyclin D1 and E2F1, respectively. Level of expression were measured 
by H-SCORE using percentage and intensity calculation. Comparisons of H-SCORE between 
groups were performed by ANOVA for parametrical data and Kruskal-Wallis for non-
parametrical data. Growth inhibition were observed after metformin treatment. Metformin 
increases Bax expression significantly at all concentrations. p21 expression was also increased 
after metformin treatment but is not statistically significant. Subsequently, metformin 
decreases cyclin D1 expression at 10 and 20 mM concentration thus decreased E2F1 
expression at 5 and 10 mM concentration. These data suggest that metformin may have 
potential therapeutic effects in mutant p53 colon cancer cell line by targeting p53-related 
molecules. 
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INTRODUCTION 
 
Colon cancer is malignancy in the 
gastrointestinal tract which cause high mortality 
rates in global cancer population. Colon cancer 
is third most common cancer in males and the 
second in females. Colon cancer incidence was 
decreased in recent years in developed 
countries due to increase of patient treatment 
quality and early detection. Unfortunately, 
incidence of colon cancer in low risk area 
which include developing countries was 
increased. 
Chemotherapy remains one of 
therapeutic option for colon cancer treatment. 
Chemotherapy act as adjuvant by reducing risk 
of relapse and patient death. Therefore, use of 
chemotherapy is still controversial due to its 
effectiveness and adverse effects. As reported 
by O’Connor, et al, no survival benefit were 
found in stage II colon cancer patients with 
poor prognostic features nor for no poor 
prognostic features after chemotherapy 
treatment. Moreover, some colon cancer 
chemotherapy regimen such as 5-fluorouracil 
(5-FU) could cause fatal adverse effect. 
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Metformin is a biguanide which has 
potential anticancer effect. Landman, et al 
reported that use of metformin related to lower 
cancer risk in diabetes type II patient. More 
specific, Zhang, et al., reported use of 
metformin reduced risk of colon cancer 
significantly. Interestingly, metformin could 
has benefit to non-diabetic patients also as 
suggested by Hosono, et al.  
In their study, metformin inhibited 
growth of colon cancer marker, aberrant crypt 
foci (ACF), consistently with decreased 
proliferating cell nuclear antigen index. 
In vitro study could help to understand 
underlying molecular anticancer mechanism of 
metformin. Alimova, et al,. found that cytotoxic 
effect of metformin in breast cancer cell line 
influenced by cell cycle arrest and altered 
erbB2 receptor tyrosine kinase (RTK) 
pathways. Cytotoxic effect of metformin were 
also found in p53-deficient colon cancer cell 
line. Zakikhani, et al., reported inhibition of 
colon cancer cell line consistent with increased 
AMP-activated protein kinase (AMPK) 
activity.  
In present study, we investigate potential 
anticancer of metformin in p53-deficient colon 
cancer cell line by assess the following p53-
related molecules: p21 (a cyclin-dependent 
kinase inhibitor) and Bax (a pro-apoptotic 
molecule). We also assess an oncogenic 
molecules expression, cyclin D1 and E2F1 
which is downstream target of cyclin D1. 
 
MATERIALS AND METHODS 
 
Antibodies.  
Mouse monoclonal antibodies included anti-
human cyclin D1 and anti-human E2F1 from 
Neomarker (CA, USA), anti-human p21 and 
anti-human Bax from Biocare (Concord, CA, 
USA). 
 
Reagents  
Metformin was obtained from Dr. Endang 
Lukitaningsih, Faculty of Pharmacy, Gadjah 
Mada University, Indonesia. It was used across 
a range of concentrations at 5, 10 and 20 mM 
diluted in media.  
 
Cell line and culture conditions 
The human colon cancer line WiDr was 
obtained from Parasitology Laboratory of 
Gadjah Mada University in Indonesia. Cell line 
was maintained in RPMI1640 medium 
supplemented with 10% fetal bovine serum 
(FBS) cultured at 37°C humidified atmosphere 
containing 95% air and 5% CO2. Cells were 
passaged by 0.25% Trypsin-EDTA when they 
reached 80% confluence. Chemicals were 
purchased from Neomarker (CA, USA). 
 
Cell proliferation assay  
Cells were plated onto 96-well plates at 3.5 x 
10
4
 cells well. After 24 hours in culture, the 
medium was removed and replaced by medium 
with (treatment) or without (control) metformin 
for 48 hours. The effect of metformin on WiDr 
cell line was evaluated by MTT assay (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide), wells were read at 490 nM with a 
microplate reader. The percentages of surviving 
cells from each group relative to control defined 
as 100% survival. 
 
Immunohistochemistry 
Protein expression of Bax, p21, cyclin D1, and 
E2F1 was assessed by using 
immunohistochemistry staining against 
monoclonal antibodies anti-human Bax, p21, 
cyclin D1, and E2F1. Methanol-fixed cells were 
stained with hematoxylin and eosin evaluated 
microscopically. After Bax, p21, cyclin D1, and 
E2F1 primary antibodies, the secondary 
antibody was anti-mouse and third step was 
ABC complex (Streptavidin-Biotin peroxidase) 
and DAB (3,3’-diaminobenzidine) chromogen. 
Scores of immunostaining were calculated by 
multiplying the percentage of labeled cells with 
the intensity (1+,2+,3+) of staining for a total 
score gain from 0 to 300. Thus the formula 
could be aplied by: 
H-SCORE= (3 x % of strong intensity 
cells) + (2 x % of moderate intensity cells) + (1 
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x weak intensity cells) + (0 x negative intensity 
cells). 
 
Statistical analysis 
 =Values are expressed as the mean ± SD in the 
bar graphs. The significance of the difference 
between the control and each experimental test 
condition was analyzed by ANOVA and 
Kruskall-Wallis test and p<0.05 was considered 
statistically significant. 
 
RESULTS 
 
Metformin induces growth inhibition of 
colon cancer cell line 
As shown in Fig. 1, metformin inhibits growth 
of WiDr cell line in a dose dependent manner. 
Three metformin concentrations (5 mM, 10 
mM, and 20 mM) significantly reduced WiDr 
cell line viability. 
 
 
 
Metformin increases apoptotic activity 
by inducing Bax expression levels 
Apoptotic activity of WiDr cell line was 
significantly increased after metformin 
treatment as shown by Fig. 2 increased Bax 
expression levels. Bax was increased at 5 and 
10 mM metformin concentrations. Maximum 
Bax expression levels were observed at 20 mM 
concentration. 
 
Metformin inhibits cell cycle-related 
molecule and increases its inhibitor 
Metformin shown to influence cell cycle 
activity by targeting cyclin D1 and p21 (Fig. 3). 
Metformin significantly inhibited cyclin D1 
expression at 10 mM and 20 mM. Decreased 
cyclin D1 expression was also found at 5 mM 
metformin but is not statistically significant. 
Consistent with decreased cyclin D1 
expression, metformin induces p21 expression 
but is not statistically significant between 
groups. 
 
 
 
 
 
Figure 1. Metformin induces growth inhibition of colon cancer cell line. WiDr cell line were seeded onto 
96-well plates and treated by metformin followed by incubation at 37°C with 5% CO2. The effects of 
metformin treatment were assessed by MTT assay after 24 hours. Data presented as mean  standard 
deviation. *p<0.05 versus control. 
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Figure 2. Metformin increases Bax expression levels. After metformin treatment, IHC was conducted to 
assess Bax expression. Cell percentage and intensity were calculated to measure H-SCORE. Data 
presented as mean  standard deviation. *p<0.05 versus control. 
 
 
 
 
 
 
 
Figure 3. Metformin alters cyclin D1 and p21 expression levels. Metformin decreases cyclin D1 expression 
levels. p21 expression levels was increased after metformin treatment but is not statistically significant. 
Data presented as mean  standard deviation. *p<0.05 versus control. 
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Metformin also altered E2F1 
expression levels. Significant increased E2F1 
expressions were observed at 5 mM and 10 
mM metformin. Metformin sharply reduced 
E2F1 expression at 5 mM. Moderate 
reduction of E2F1 was found at 10 mM 
metformin. Metformin also reduced at 20 mM 
metformin but is not statistically significant 
(Fig. 4). 
 
DISCUSSION 
 
p53 has pivotal role in cancer 
development by controlling cell homeostasis. 
It regulates cell growth and cell senescence 
by apoptosis, cell cycle, and DNA repair 
regulatory mechanism. Dysregulation of p53 
and its related molecules functions causes 
uncontrolled cell growth leading to 
malignancy. Mutation in p53 gene has been 
reported in half of colorectal cancer case. 
p53 controls intrinsic apoptosis 
pathway by activating pro apoptosis activities. 
By targeting several genes such as Bax, noxa 
and puma, p53 could induce cytochorme-c 
release into cytoplasm from mitochondria. 
This processes lead to protease cascade which 
end to cell execution by caspase-3. p53 
contribution in extrinsic apoptosis pathway 
was also reported. p53 regulates extrinsic 
apoptosis pathway  related molecules such as 
Fas ligand which subsequently induce 
apoptosis. 
Cell cycle is a complex system which 
regulate cell proliferation. Cell cycle 
controlled by interaction of several molecules 
such as cyclins and cyclin dependent kinases 
(CDKs). For example, cyclin D1 promotes 
cell progression in G1 phase when cyclin E 
promotes progression in mid late G1 phase 
and early S phase. This processes induced by 
formation complex with CDKs. CDK4 and 
CDK6 activity relates to cyclin D1 and CDK2 
relates to cyclin E function. Moreover, 
cyclins-CDKs complexes could 
phosphorylate Rb-E2F1 complexes protein 
which lead to E2F1 release. E2F is a family 
molecules which responsible to up regulation 
of cancer promoting genes such as CCNE, 
CCNA and Myc. 
 
Metformin inhibits E2F1 expression levels 
 
 
Figure 4. Metformin decreases E2F1 expression levels. At 5 mM and 10 mM concentrations, metformin 
significantly decreases E2F1 expression levels. Data presented as mean  standard deviation. * p<0.05 
versus control. 
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Figure 5. Metformin alters p53-related molecules in WiDr cell line. Representative image (magnification x 
400) of IHC analysis after metformin treatment in WiDr cell line.  
 
 
p21 is a p53 related protein which also 
regulate cell cycle. Harper and colleagues 
reported that p21 is potent inhibitor of CDKs 
such as CDK2, CDK4, and CDK6. Impairment 
of cyclins and CDKs complexes result in cell 
cycle arrest. 
In our study, we used WiDr cell line to evaluate 
effects of metformin in p53 deficient colon 
cancer cell line. We reported that metformin 
induced Bax expression significantly (Fig. 2). 
Our finding consistent to previous study by 
Buzzai and colleagues. They reported that 
metformin induced Bax expression in p53 
deficient colon cancer cell line. As per Suzuki, 
et al. report, Bax could be induced by p19 in a 
p53 independent pathway. 
In this study, metformin induced p21 
expression but is not statistically significant 
(Fig. 3). Takhahasi and colleagues also found 
that increase of p21 expression by metformin 
could be in a functional p53 independent 
pathway. p21 which is normally transcriptional 
target by p53 could be induced by others 
mechanisms such as post transcriptional and 
post translational mechanism.  
These events followed by decrease of 
cyclin D1 (Fig. 3) and and its downstream 
target, E2F1 (Fig. 4), significantly. Metformin 
is a LKB1/AMPK pathway activator drug. 
Activated AMPK could alter its downstream 
target including cyclin D1 (20). Zhuang and 
Miskimins Reported that metformin induced 
AMPK activity which subsequently decreased 
cyclin D1 expressions. Decrease of cyclin D1 
expression would also reduce Rb-E2F1 
complexes phosphorylation thus decrease E2F1 
release and activity. 
 
CONCLUSIONS 
 
Our study supports previous studies 
which evaluate effect of metformin for cancer 
treatment in vitro. Moreover, its results also 
indicates metformin treatment could influence 
p53 related molecules in p53 mutant colon 
cancer cell line. Thus metformin treatment 
might beneficial for p53 mutated colon cancer 
patients.  
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